Awareness, perception and utilization of a mobile health clinic by people who use drugs

References

• Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–181.
   PubMed Web of Science ®Google Scholar
• Cranston K, Alpren C, John B, et al. Notes from the field: HIV diagnoses among persons who inject drugs - Northeastern Massachusetts, 2015-2018. Morb Mortal Wkly Rep. 2019;68(10):253–254.
   PubMed Web of Science ®Google Scholar
• Scholl L, Seth P, Kariisa M, et al. Drug and opioid-involved overdose deaths—United States, 2013–2017. Morb Mortal Wkly Rep. 2018;67(5152):1419–1427.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. Atlanta (GA): Centers for Disease Control and Prevention; 2020 [cited 17 May 2021]. Available from: https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
   Google Scholar
• Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am. 2002;16(3):697–712.
   PubMed Web of Science ®Google Scholar
• Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend. 2012;124(1–2):70–78.
   PubMed Web of Science ®Google Scholar
• Schulte MT, Hser YI. Substance use and associated health conditions throughout the lifespan. Public Health Rev. 2013;35(2):3.
   Google Scholar
• Goldner EM, Lusted A, Roerecke M, et al. Prevalence of axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014;39(3):520–531.
   PubMed Web of Science ®Google Scholar
• Visconti AJ, Sell J, Greenblatt AD. Primary care for persons who inject drugs. Am Fam Physician. 2019;99(2):109–116.
   PubMed Web of Science ®Google Scholar
• Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344–350.
   PubMed Web of Science ®Google Scholar
• Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the US opioid crisis. Mol Psychiatry. 2021;26(1):41–50.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244–250.
   PubMed Web of Science ®Google Scholar
• Lin LA, Bohnert AS, Blow FC, et al. Polysubstance use and association with opioid use disorder treatment in the US veterans health administration. Addiction. 2021;116(1):96–104.
   PubMed Web of Science ®Google Scholar
• Shearer RD, Howell BA, Bart G, et al. Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015-2018. Drug Alcohol Depend. 2020;214:108162.
   PubMed Web of Science ®Google Scholar
• Cai Y, Dai Z, Wen S, et al. Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infect Dis. 2020;20(1):1.
   Web of Science ®Google Scholar
• Al-Tayyib A, Koester S, Langegger S, et al. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Meacham MC, Rudolph AE, Strathdee SA, et al. Polydrug use and HIV risk among people who inject heroin in tijuana, Mexico: a latent class Analysis. Subst Use Misuse. 2015;50(10):1351–1359.
   PubMed Web of Science ®Google Scholar
• Neale J, Tompkins C, Sheard L. Barriers to accessing generic health and social care services: a qualitative study of injecting drug users. Health Soc Care Community. 2008;16(2):147–154.
   PubMed Web of Science ®Google Scholar
• Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–110.
   PubMed Web of Science ®Google Scholar
• Miller-Lloyd L, Landry J, Macmadu A, et al. Barriers to healthcare for people who inject drugs: a survey at a syringe exchange program. Subst Use Misuse. 2020;55(6):896–899.
   PubMed Web of Science ®Google Scholar
• Motavalli D, Taylor JL, Childs E, et al. “Health is on the back burner:” multilevel barriers and facilitators to primary care among people who inject drugs. J Gen Intern Med. 2021;36(1):129–137.
   PubMed Web of Science ®Google Scholar
• Meyerson BE, Russell DM, Kichler M, et al. I don’t even want to go to the doctor when I get sick now: healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112.
   PubMed Web of Science ®Google Scholar
• Artenie AA, Jutras‐Aswad D, Roy É, et al. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015;22(10):792–799.
   PubMed Web of Science ®Google Scholar
• Chitwood DD, Sanchez J, Comerford M, et al. Primary preventive health care among injection drug users, other sustained drug users, and non-users. Subst Use Misuse. 2001;36(6–7):807–823.
   PubMed Web of Science ®Google Scholar
• Saitz R, Mulvey KP, Samet JH. The substance‐abusing patient and primary care: linkage via the addiction treatment system? Subst Abus. 1997;18(4):187–195.
   Google Scholar
• Harris M. Normalised pain and severe health care delay among people who inject drugs in london: adapting cultural safety principles to promote care. Soc Sci Med. 2020;260:113183.
   PubMed Web of Science ®Google Scholar
• Office of the Surgeon General (US). Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health. Washington (DC): Office of the Surgeon General; 2016.
   Google Scholar
• Kendall CE, Boucher LM, Mark AE, et al. A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada. Harm Reduct J. 2017;14(1):1–0.
   PubMedGoogle Scholar
• Lewer D, Freer J, King E, et al. Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2020;115(6):1011–1023.
   PubMed Web of Science ®Google Scholar
• Nambiar D, Spelman T, Stoove M, et al. Are people who inject drugs frequent users of emergency department services? A cohort study (2008-2013). Subst Use Misuse. 2018;53(3):457–465.
   PubMed Web of Science ®Google Scholar
• Chen IM, Huang CL, Yeh BJ, et al. Health service utilization of heroin abusers: a retrospective cohort study. Addict Behav. 2015;45:281–286.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Lewis DC, O’Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–1695.
   PubMed Web of Science ®Google Scholar
• Giacomuzzi SM, Ertl M, Kemmler G, et al. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005;5:452–468.
   PubMedGoogle Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225.
   PubMed Web of Science ®Google Scholar
• Schwarz R, Zelenev A, Bruce RD, et al. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat. 2012;43(4):451–457.
   PubMed Web of Science ®Google Scholar
• Kresina TF, Lubran R. Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health. 2011;8(10):4102–4117.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41(6):891–896.
   PubMed Web of Science ®Google Scholar
• Tsui JI, Evans JL, Lum PJ, et al. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–1981.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). Federal guidelines for opioid treatment programs. HHS publication no. (SMA) PEP15-FEDGUIDEOTP. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015.
   Google Scholar
• Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133.
   PubMed Web of Science ®Google Scholar
• Cioe K, Biondi BE, Easly R, et al. A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:108146.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
   PubMed Web of Science ®Google Scholar
• Kermack A, Flannery M, Tofighi B, et al. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Rosenblatt RA, Andrilla CH, Catlin M, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.
   PubMed Web of Science ®Google Scholar
• Hatcher AE, Mendoza S, Hansen H. At the expense of a life: race, class, and the meaning of buprenorphine in pharmaceuticalized “care”. Subst Use Misuse. 2018;53(2):301–310.
   PubMed Web of Science ®Google Scholar
• Yarborough BJ, Stumbo SP, McCarty D, et al. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–118.
   PubMed Web of Science ®Google Scholar
• Peterson JA, Schwartz RP, Mitchell SG, et al. Why don’t out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy. 2010;21(1):36–42.
   PubMed Web of Science ®Google Scholar
• Godersky ME, Saxon AJ, Merrill JO, et al. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14(1):11.
   PubMedGoogle Scholar
• Madden EF. Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324–331.
   PubMed Web of Science ®Google Scholar
• Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014;311(14):1393–1394.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.
   PubMed Web of Science ®Google Scholar
• Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80–86.
   PubMed Web of Science ®Google Scholar
• Strike C, Millson M, Hopkins S, et al. What is low threshold methadone maintenance treatment? Int J Drug Policy. 2013;24(6):e51–e56.
   PubMedGoogle Scholar
• Edland-Gryt M, Skatvedt AH. Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders. Int J Drug Policy. 2013;24(3):257–264.
   PubMed Web of Science ®Google Scholar
• Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20.
   PubMedGoogle Scholar
• Hill CF, Powers BW, Jain SH, et al. Mobile health clinics in the era of reform. Am J Manag Care. 2014;20(3):261–264.
   PubMed Web of Science ®Google Scholar
• Malone NC, Williams MM, Smith Fawzi MC, et al. Mobile health clinics in the United States. Int J Equity Health. 2020;19(1):40.
   PubMed Web of Science ®Google Scholar
• Hill C, Zurakowski D, Bennet J, et al. Knowledgeable neighbors: a mobile clinic model for disease prevention and screening in underserved communities. Am J Public Health. 2012;102(3):406–410.
   PubMed Web of Science ®Google Scholar
• Yu SW, Hill C, Ricks ML, et al. The scope and impact of mobile health clinics in the United States: a literature review. Int J Equity in Health. 2017;16(1):178.
   PubMedGoogle Scholar
• Aung KK, Hill C, Bennet J, et al. The emerging business models and value proposition of mobile health clinics. Am J Accountable Care. 2015;3(4):36–40.
   PubMedGoogle Scholar
• Chen YR, Chang-Halpenny C, Kumarasamy NA, et al. Perspectives of mobile versus fixed mammography in Santa Clara County, California: a focus group study. Cureus. 2016;8(2):e494.
   PubMedGoogle Scholar
• Guruge S, Hunter J, Barker K, et al. Immigrant women’s experiences of receiving care in a mobile health clinic. J Adv Nurs. 2010;66(2):350–359.
   PubMed Web of Science ®Google Scholar
• Carmack HJ. “What happens on the van, stays on the van”: the (re)structuring of privacy and disclosure scripts on an Appalachian mobile health clinic. Qual Health Res. 2010;20(10):1393–1405.
   PubMed Web of Science ®Google Scholar
• Altice FL, Springer S, Buitrago M, et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80(3):416–427.
   PubMed Web of Science ®Google Scholar
• Altice FL, Bruce RD, Walton MR, et al. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005;82(1):151–161.
   PubMed Web of Science ®Google Scholar
• Morano JP, Zelenev A, Lombard A, et al. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health. 2014;39(5):922–934.
   PubMed Web of Science ®Google Scholar
• Morano JP, Zelenev A, Walton MR, et al. Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model. Am J Public Health. 2014;104(8):1508–1515.
   PubMed Web of Science ®Google Scholar
• Bouchelle Z, Rawlins Y, Hill C, et al. Preventative health, diversity, and inclusion: a qualitative study of client experience aboard a mobile health clinic in Boston, Massachusetts. Int J Equity Health. 2017;16(1):191.
   PubMedGoogle Scholar
• de Peralta AM, Gillispie M, Mobley C, et al. It’s all about trust and respect: cultural competence and cultural humility in mobile health clinic services for underserved minority populations. J Health Care Poor Underserved. 2019;30(3):1103–1118.
   PubMed Web of Science ®Google Scholar
• Bauman AE, Fardy HJ, Harris PG. Getting it right: why bother with patient-centred care? Med J Aust. 2003;179(5):253–256.
   PubMed Web of Science ®Google Scholar
• Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. 2000;49(9):796–804.
   PubMed Web of Science ®Google Scholar
• Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013;3(1):e001570.
   PubMed Web of Science ®Google Scholar
• Rosecrans A, Harris R, Saxton RE, et al. Mobile low-threshold buprenorphine integrated with infectious disease services. J Subst Abuse Treat. 2021:108553.
   PubMed Web of Science ®Google Scholar
• Maryland Department of Health and Mental Hygiene. Unintentional drug- and alcohol-related intoxication deaths in Maryland, 2019. Baltimore (MD): Maryland Department of Health and Mental Hygiene; 2020.
   Google Scholar
• Morse JM. Determining sample size. Qual Health Res. 2000;10(1):3–5.
   Web of Science ®Google Scholar
• Lincoln YS, Guba EG. Naturalistic inquiry. Newbury Park (CA): Sage; 1985.
   Google Scholar
• Creswell JW. Qualitative inquiry & research design: choosing among five approaches. 3rd ed. Thousand Oaks (CA): Sage; 2013.
   Google Scholar
• Warren CA. Qualitative interviewing. In JF Gubrium, JA Holstein, editors. Handbook of interview research: context and method. Thousand Oaks (CA): Sage; 2002. p. 83–101.
   Google Scholar
• Morse JM. The significance of saturation. Qual Health Res. 1995;5(2):147–149.
   Web of Science ®Google Scholar
• Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.
   Web of Science ®Google Scholar
• Saldafia J. The coding manual for qualitative researchers. London (UK): Sage; 2009.
   Google Scholar
• Glaser BG. The constant comparative method of qualitative analysis. Soc Probl. 1965;12(4):436–445.
   Web of Science ®Google Scholar
• Thorne S. Data analysis in qualitative research. Evid Based Nurs. 2000;3(3):68–70.
   Google Scholar
• Martin SA, Chiodo LM, Bosse JD, et al. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• Roy PJ, Choi S, Bernstein E, et al. Appointment wait-times and arrival for patients at a low-barrier access addiction clinic. J Subst Abuse Treat. 2020;114:108011.
   PubMed Web of Science ®Google Scholar
• Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95–98.
   PubMed Web of Science ®Google Scholar
• Perreault M, Rousseau M, Mercier C, et al. Accessibility to methadone substitution treatment: the role of a low-threshold program. Can J Public Health. 2003;94(3):197–200.
   PubMedGoogle Scholar
• Stancliff S, Joseph H, Fong C, et al. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York city: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278–287.
   PubMed Web of Science ®Google Scholar
• Nordeck CD, Buresh M, Krawczyk N, et al. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J Addict Med. 2021;15(5):364–369.
   PubMed Web of Science ®Google Scholar
• Langendam MW, van Brussel GH, Coutinho RA, et al. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774–780.
   PubMed Web of Science ®Google Scholar
• Nolan S, Hayashi K, Milloy MJ, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015;156:57–61.
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York city. Drug Alcohol Depend. 2016;164:14–21.
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, et al. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981.
   PubMed Web of Science ®Google Scholar
• Kohler RE, Roncarati JS, Aguiar A, et al. Trauma and cervical cancer screening among women experiencing homelessness: a call for trauma-informed care. Womens Health. 2021;17:17455065211029238.
   Web of Science ®Google Scholar
• Wood TJ, Koester KA, Christopoulos KA, et al. If someone cares about you, you are more apt to come around: improving HIV care engagement by strengthening the patient-provider relationship. Patient Prefer Adherence. 2018;12:919–927.
   PubMed Web of Science ®Google Scholar
• Remien RH, Bauman LJ, Mantell J, et al. Barriers and facilitators to engagement of vulnerable populations in HIV primary care in New York city. J Acquir Immune Defic Syndr. 2015;69(1):S16–S24.
   PubMedGoogle Scholar
• Salvalaggio G, McKim R, Taylor M, et al. Patient–provider rapport in the health care of people who inject drugs. Sage Open. 2013;3(4):215824401350925.
   Google Scholar
• Rodriguez KL, Appelt CJ, Young AJ, et al. African American veterans’ experiences with mobile geriatric care. J Health Care Poor Underserved. 2007;18(1):44–53.
   PubMed Web of Science ®Google Scholar
• Fine DR, Weinstock K, Plakas I, et al. Experience with a mobile addiction program among people experiencing homelessness. J Health Care Poor Underserved. 2021;32(3):1145–1154.
   PubMed Web of Science ®Google Scholar
• Muncan B, Walters SM, Ezell J, et al. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York city. Harm Reduct J. 2020;17(1):1–9.
   PubMed Web of Science ®Google Scholar
• Grau LE, Arevalo S, Catchpool C, et al. Expanding harm reduction services through a wound and abscess clinic. Am J Public Health. 2002;92(12):1915–1917.
   PubMed Web of Science ®Google Scholar
• Lang K, El-Aneed A, Berenbaum S, et al. Qualitative assessment of crisis services among persons using injection drugs in the city of Saskatoon. J Subst Use. 2013;18(1):3–11.
   Web of Science ®Google Scholar
• Sacamano P, Krawczyk N, Latkin C. Emergency department visits in a cohort of persons with substance use: incorporating the role of social networks. Subst Use Misuse. 2018;53(13):2265–2269.
   PubMed Web of Science ®Google Scholar
• Latkin CA, Knowlton AR. Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care. 2005;17(1):102–113.
   PubMed Web of Science ®Google Scholar
• Li J, Weeks MR, Borgatti SP, et al. A social network approach to demonstrate the diffusion and change process of intervention from peer health advocates to the drug using community. Subst Use Misuse. 2012;47(5):474–490.
   PubMed Web of Science ®Google Scholar
• Marshall Z, Dechman MK, Minichiello A, et al. Peering into the literature: a systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend. 2015;151:1–4.
   PubMed Web of Science ®Google Scholar
• Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep. 2002;117(1):S135–S145.
   PubMedGoogle Scholar
• Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. 86 FR 22439. Fed Regist. 2021;86(80):22439–22440.
   Google Scholar
• Conner KO, Rosen D. “You’re nothing but a junkie”: multiple experiences of stigma in an aging methadone maintenance population. J Soc Work Pract Addict. 2008;8(2):244–264.
   Google Scholar